Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1785 | Knowledge, Attitude, Practice, Awareness, Preference Wiki | 0.35 |
| drug3260 | Standard-of-care Wiki | 0.35 |
| drug1188 | Endoscopic intervention Wiki | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1518 | Hydrogen Oxygen Generator with Nebulizer Wiki | 0.35 |
| drug1018 | Delayed diagnostics Anyplex TMII RV16 Detection Wiki | 0.35 |
| drug182 | AdimrSC-2f Wiki | 0.35 |
| drug2170 | Nebulized administration of RLF-100 or Placebo Wiki | 0.35 |
| drug2809 | Rapid diagnostics using Anyplex TMII RV16 Detection Wiki | 0.35 |
| drug2776 | RLF-100 (aviptadil) Wiki | 0.25 |
| drug995 | Data Collection Wiki | 0.25 |
| drug2767 | RECOP unit patient Wiki | 0.25 |
| drug2200 | Nitric Oxide Wiki | 0.18 |
| drug304 | Ascorbic Acid Wiki | 0.18 |
| drug908 | Convalescent plasma Wiki | 0.08 |
| drug2505 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004417 | Dyspnea NIH | 0.94 |
| D005335 | Fever of Unknown Origin NIH | 0.35 |
| D002637 | Chest Pain NIH | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D063806 | Myalgia NIH | 0.35 |
| D055370 | Lung Injury NIH | 0.14 |
| D004630 | Emergencies NIH | 0.06 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| D055371 | Acute Lung Injury NIH | 0.06 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.06 |
| D011024 | Pneumonia, Viral NIH | 0.04 |
| D007239 | Infection NIH | 0.04 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| D011014 | Pneumonia NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003326 | Myalgia HPO | 0.35 |
| HP:0100749 | Chest pain HPO | 0.35 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 8 clinical trials
Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs. A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed. In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described. The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.
Description: The number of days in hospital within one month after randomization
Measure: Duration of hospitalization Time: One monthDescription: Number of days on antimicrobials within one month after randomization
Measure: Antimicrobial consumption Time: One monthDescription: Defined daily doses of antimicrobial agents within one month after randomization
Measure: Antimicrobial consumption Time: One monthThe scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.
Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.
Measure: Reduction in the incidence of intubation and mechanical ventilation Time: 28 daysDescription: Mortality from all causes
Measure: Mortality Time: 28 daysDescription: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab
Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract Time: 7 daysDescription: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).
Measure: Time to clinical recovery Time: 28 daysBrief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or mechanical ventilation. Mortality rates as high as 80% have been reported among those who require mechanical ventilation, despite best available intensive care. Patients with moderate and severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized RLF-100 (aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP)) 100 μg 3x daily plus Standard of Care vs. placebo + Standard of Care using an FDA 501(k) cleared mesh nebulizer. The primary outcome will be progression to in severity of COVID-19 (i.e. moderate progressing to to severe or critical OR severe progressing to critical) over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.
Description: Progression to ARDS is defined as the need for mechanical ventilation
Measure: Progression to ARDS Time: 28 daysDescription: Blood PO2 as measured by pulse oximetry
Measure: Blood oxygenation Time: 28 daysDescription: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath = very mild shortness of breath = mild shortness of breath = moderate shortness of breath or breathing difficulty = somewhat severe shortness of breath = strong or hard breathing 7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity
Measure: RDP Dsypnea Scale Time: 28 daysDescription: Distance walked in six minutes
Measure: Distance walked in six minutes Time: 28 daysThis was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge. Patients in control group received standard-of-care (consisting of oxygen therapy) alone until discharge.
Description: The proportion of patients with improved disease severity (by at least one scale) at day 2
Measure: The proportion of patients with improved disease severity at day 2 Time: from baseline to day 2Description: The proportion of patients with improved disease severity (by at least one scale) at day 3
Measure: The proportion of patients with improved disease severity at day 3 Time: from baseline to day 3Description: The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge
Measure: The proportion of patients with improved disease severity at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in oxygen saturation at day 2.
Measure: The change from baseline in oxygen saturation at day 2. Time: from baseline to day 2Description: The change from baseline in oxygen saturation at day 3.
Measure: The change from baseline in oxygen saturation at day 3. Time: from baseline to day 3Description: The change from baseline in oxygen saturation at the day before hospital discharge.
Measure: The change from baseline in oxygen saturation at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in dyspnea scale at day 2. Time: from baseline to day 2Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in dyspnea scale at day 3. Time: from baseline to day 3Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in dyspnea scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2
Measure: The change from baseline in cough scale at day 2 Time: from baseline to day 2Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3
Measure: The change from baseline in cough scale at day 3 Time: from baseline to day 3Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge
Measure: The change from baseline in cough scale at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest pain scale at day 2. Time: from baseline to day 2Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest pain scale at day 3. Time: from baseline to day 3Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest pain scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest distress scale at day 2. Time: from baseline to day 2Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest distress scale at day 3. Time: from baseline to day 3Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest distress scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)The general aim of this study is to estimate the rate of disease progression for adults who seek testing and test positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations, special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-Cov-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.
Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.
Measure: Time to Hospitalization Time: 28 daysDescription: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.
Measure: Time to Expiration Time: 28 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.
Measure: Rate of Death at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.
Measure: Rate of Death at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.
Measure: Rate of Death at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.
Measure: Rate of Hospitalization at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.
Measure: Rate of Hospitalization at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.
Measure: Rate of Hospitalization at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.
Measure: Participant Health at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.
Measure: Participant Health at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.
Measure: Participant Health at 28 Days Time: 28 daysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 7 Days Time: 7 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 14 Days Time: 14 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 28 Days Time: 28 DaysThis research aims to improve our knowledge of the epidemiology of patients consulting in the COvid-19 Possible REspiratory Units (RECOP unit). Indeed, the epidemic linked to COVID-19 affects France and impacts its health system. The reception of all intermediate patients will be on the Emergency Structures (SU). Indeed, the French healthcare system centralizes unscheduled urgent care on the ER. The aspecific respiratory symptomatology in "intermediate" patients indicates them all the more at an admission to SU or the diagnostic approach to respiratory difficulty may be carried out. A central issue of this diagnostic strategy will be to be rapid, since the diagnosis will have to be made in the context of significant flows, with a need to quickly refer patients to the most suitable downstream service, while limiting the risk contamination of caregivers and vulnerable patients if a COVID-19 + patient is admitted to an unsuitable service. However, virological tests do not currently allow rapid results for COVID-19. Research project of investigatory aims to develop a predictive model of the risk of being COVID-19 positive for patients admitted to the emergency room for acute dyspnea.
Description: demographic variables, usual history and treatments, episode characteristics (symptomatology, evolution, treatment taken) and data from the initial clinical examination will be collected by doctor
Measure: Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea Time: inclusion dayDescription: The COVID-19 virological condition will be taken with PCR tests on naso-pharyngeal samples or on sputum for patients taking
Measure: Describe the characteristics of patients admitted to reCOP units according to their virological status Time: 30 daysDescription: Virological status will be collected by a phone call at the patient
Measure: Virological status Time: 30 daysDescription: Mortality status will be collected by a phone call at the patient
Measure: Mortality status Time: 30 daysCoronavirus disease 2019 (abbreviated "COVID- 19") is a pandemic respiratory disease that is caused by a novel coronavirus and was first detected in December 2019 in Wuhan, China. The disease is highly infectious, and its main clinical symptoms include fever, dry cough, fatigue, myalgia, and dyspnoea.1 In China, 18.5% of the patients with COVID-19 developed to the severe stage, which is characterized by acute respiratory distress syndrome, septic shock, difficult-to-tackle metabolic acidosis, and bleeding and coagulation dysfunction. After China, COVID-19 spread across the world and many governments implemented unprecedented measures like suspension of public transportation, the closing of public spaces, close management of communities, and isolation and care for infected people and suspected cases. The Malaysian government had enforced Movement Control Order (MCO) from 18th March to 4th May 2020 and henceforth Conditional Movement Control Order (CMCO) until 9th June 2020. The battle against COVID-19 is still continuing in Malaysia and all over the world. Due to the CMO and CMCO in the country, public and private universities have activated the e-learning mode for classes and as the government ordered, universities are closed and no face-to-face activities allowed. This has forced students of all disciplines including dentistry to stay at home which are wide-spread across Malaysia and shift to e- learning mode. To guarantee the final success for fight against COVID-19, regardless of their education status, students' adherence to these control measures are essential, which is largely affected by their knowledge, attitudes, and practices (KAP) towards COVID-19 in accordance with KAP theory. Once the restrictions are eased students have to come back and resume their clinical work in the campus. Hence, in this study we assessed the Knowledge, Attitude, and Practice (KAP) towards COVID-19 and the students preference for online learning.
Description: KAP towards COVID-19 was assessed using validated questionnnaire
Measure: Knowledge, Attitude, Practice of dental students towards COVID-19 Time: 4 monthsDescription: Awareness level about Infection control to prevent COVID-19 transmission in clinics was assesed using a standardized questionnaire
Measure: Awareness level about Infection control to prevent COVID-19 transmission in clinics Time: 4 monthsDescription: Preference towards online learning. was assessed using a standard questionnaire
Measure: Preference towards online learning. Time: 4 monthsThe objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.
Description: The presence of respiratory sequelae will be assessed by low dose thoracic tomodensitometry
Measure: Presence of respiratory sequelae Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Forced vital capacity (FVC, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Forced vital capacity (FVC, %) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Forced expiratory volume in 1 second (FEV1, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Forced expiratory volume in 1 second (FEV1, %) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Tiffeneau-Pinelli index (FEV1/FVC, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Tiffeneau-Pinelli index (FEV1/FVC, %) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Total lung capacity (TLC, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Total lung capacity (TLC, %) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Residual volume (RV, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Residual volume (RV, %) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: RV/TLC ratio (%) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: RV/TLC ratio (%) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Maximal inspiratory pressure (MIP, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Maximal inspiratory pressure (MIP, %) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Maximal expiratory pressure (MEP, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Maximal expiratory pressure (MEP, %) Time: 3 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %) Time: 6 months after hospital dischargeDescription: Respiratory functional exploration
Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %) Time: 3 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: pH Time: 6 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: pH Time: 3 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Arterial oxygen partial pressure (PaO2, mmHg) Time: 6 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Arterial oxygen partial pressure (PaO2, mmHg) Time: 3 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg) Time: 6 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg) Time: 3 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Bicarbonate concentration (mmol/L) Time: 6 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Bicarbonate concentration (mmol/L) Time: 3 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Arterial oxygen saturation (SaO2, %) Time: 6 months after hospital dischargeDescription: Arterial gasometry will be performed under ambient air and under oxygen
Measure: Arterial oxygen saturation (SaO2, %) Time: 3 months after hospital dischargeDescription: Six-minute walk test will be performed under ambient air and under oxygen
Measure: Six-minute walk test Time: 6 months after hospital dischargeDescription: Six-minute walk test will be performed under ambient air and under oxygen
Measure: Six-minute walk test Time: 3 months after hospital dischargeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports